Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

Proceedings of the Canadian Thyroid Cancer Active Surveillance Study Group 2019 national investigator meeting

Abstract

Active surveillance (AS) in the management of small, low risk papillary thyroid cancer (PTC) as an alternative option to thyroidectomy, is an area of active research. A national Canadian study is proposed to evaluate the long-term outcomes of patients with small, low risk PTC who choose AS or surgery. This letter describes the proceedings of a national investigator meeting to plan the study.

Graphical abstract

Currently about 8600 Canadians are diagnosed with thyroid cancer per year, and this number has been rising [1]. Papillary thyroid cancer, especially low risk papillary thyroid cancer (PTC), accounts for the majority of cases [2]. Although the traditional standard management of small, low risk PTC has been thyroidectomy, there is current interest in an alternative option of active surveillance (AS). AS is close clinical and diagnostic test follow-up, with the understanding that if the disease progresses, curative intent surgery would be performed. Furthermore, patients choosing to undergo AS may change their mind and have surgery at any point in follow-up, even if the disease does not progress. Cho et al. recently reported that in a recent systematic review and meta-analysis examining AS outcomes, that within a 5-year time frame, 94.7% of untreated patients did not experience significant tumor growth and 98.4% did not experience nodal metastases [3]. Furthermore, on reviewing the relevant literature and contacting experts, we found no reports of any thyroid-cancer related deaths nor distant metastases in patients with small, low risk PTC under AS [4]. Much of the existing long-term outcome literature on thyroid cancer AS describes the clinical course of patients with papillary microcarcinoma (PTC ≤1 cm) followed in Japan [5]. A prospective study offering low risk PTC patients the choice of AS or thyroid surgery (standard of care) has been conducted at University Health Network in Toronto, Canada since May of 2016, with ongoing recruitment and follow-up [6]. Eligible patients are individuals with with small (< 2 cm maximal diameter), PTCs where the disease is confined to the thyroid (i.e. no known nodal or distant metastases nor extrathyroidal extension) and the tumor is not encroaching critical structures (trachea or course of recurrent laryngeal nerve) [6].

We herein describe the proceedings of a national investigator meeting held in Toronto on November 30, 2019, to plan a pan-Canadian prospective cohort study examining outcomes of patients with small, low risk PTC who choose AS or surgery. Ethics approval was not required as this is a summary of a meeting. The pan-Canadian study would build on the findings of the original Toronto study and ultimately the results would be reported together. The 1-day meeting was sponsored by the Canadian Institutes of Health Research (Planning Grant) and the Princess Margaret Cancer Centre Endocrine Oncology Site Group. Participants included eight head and neck surgeons, two endocrinologists, one radiologist and one statistician. There were also two patient participants invited to speak (one of whom had prior thyroidectomy for PTC and another who was under AS). The format of the scientific program was that of formal lectures with subsequent discussion. The patient participants were interviewed by a meeting host in presence of the investigators and following the interviews, the investigators had the opportunity to ask the patients’ questions. The patient participants discussed their thyroid cancer care experiences and shared insights on what they felt was important for doctors/investigators to know in caring for thyroid cancer patients. The Toronto co-primary investigators (Anna Sawka and David Goldstein) hosted/organized the meeting, moderated the discussions, and took written meeting notes. The topics discussed, all relating to low risk PTC, included: a) Review of the current experience in AS of low risk PTC – worldwide and in Canada (Toronto), b) Diagnostic imaging considerations in AS, c) Presentation and feedback on a proposed national study protocol with discussion of feasibility considerations, d) Statistical design/sample size considerations, e) Patient perspectives (interview of 2 individuals), and f) Ideas for possible future ancillary studies. The key concepts distilled from the meeting by the co-primary investigators are shown in Table 1. In concluding the meeting, the group strongly agreed that a multi-center prospective observational cohort study comparing AS and surgery for small, low risk PTC is feasible to perform in Canada. Furthermore, the participants agreed to work together in conducting such a study, across multiple Canadian institutions (operating funds for the initiation of this pan-Canadian study secured from the Canadian Institutes of Health Research and the Canadian Cancer Society).

Table 1 Key concepts at from a Canadian national investigator meeting regarding research on AS for low risk PTC

Availability of data and materials

Not applicable.

Abbreviations

PTC:

Papillary thyroid cancer

AS:

Active surveillance

References

  1. Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199–205. https://doi.org/10.1503/cmaj.191292.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357–61. https://doi.org/10.1503/cmaj.061730.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cho SJ, Suh CH, Baek JH, Chung SR, Choi YJ, Chung KW, et al. Active surveillance for small papillary thyroid cancer: a systematic review and meta-analysis. Thyroid. Oct 2019;29(10):1399–408. https://doi.org/10.1089/thy.2019.0159.

    Article  PubMed  Google Scholar 

  4. Sawka AM, Thabane L. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis-methodologic critiques and tips for addressing them [published online ahead of print, 2020 Apr 9]. Surgery. 2020;Surgery. 2020;168(5):975.

  5. Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg. 2016;40(3):516–22. https://doi.org/10.1007/s00268-015-3392-y.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sawka AM, Ghai S, Yoannidis T, Rotstein L, Gullane PJ, Gilbert RW, et al. A prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer [published online ahead of print, 2020 Apr 8]. Thyroid. 2020;30(7):999–1007. https://doi.org/10.1089/thy.2019.0592.

Download references

Acknowledgments

The authors would like to thank Dr. George Tomlinson for statistical advice in planning this study and Ms. Audrea Martin for her kind assistance in organizing this conference. The authors would also like to thank the patient representatives who participated in the meeting.

Funding

This meeting was sponsored by Planning and Dissemination Grant from the Canadian Institutes of Health Research (FRN PCS 161831) and the Princess Margaret Cancer Centre Endocrine Oncology site group. The planned study is funded by a Project Grant from the Canadian Institutes of Health Research (FRN 162314) and an Innovation to Impact Grant from the Canadian Cancer Society (FRN 706302).

Author information

Authors and Affiliations

Authors

Contributions

All authors read and approved of the manuscript as well as provided editing of the manuscript. DG, AMS, SG, GT, NNB, JJ, AG all participated in the conference design. DG and AMS wrote the manuscript.

Corresponding author

Correspondence to David P. Goldstein.

Ethics declarations

Ethics approval

Was not required as this is a summary of a meeting.

Consent for publication

All authors consent to the publication of the manuscript.

Competing interests

There are no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldstein, D.P., Ghai, S., Corsten, M. et al. Proceedings of the Canadian Thyroid Cancer Active Surveillance Study Group 2019 national investigator meeting. J of Otolaryngol - Head & Neck Surg 50, 40 (2021). https://doi.org/10.1186/s40463-021-00514-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40463-021-00514-0

Keywords